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Abstract
Background: In utero microinjection has proven valuable for exploring the developmental consequences of
altering gene expression, and for studying cell lineage or migration during the latter half of embryonic mouse
development (from embryonic day 9.5 of gestation (E9.5)). In the current study, we use ultrasound guidance to
accurately target microinjections in the conceptus at E6.5–E7.5, which is prior to cardiovascular or placental
dependence. This method may be useful for determining the developmental effects of targeted genetic or cellular
interventions at critical stages of placentation, gastrulation, axis formation, and neural tube closure.
Results: In 40 MHz ultrasound images at E6.5, the ectoplacental cone region and proamniotic cavity could be
visualized. The ectoplacental cone region was successfully targeted with 13.8 nL of a fluorescent bead suspension
with few or no beads off-target in 51% of concepti microinjected at E6.5 (28/55 injected). Seventy eight percent
of the embryos survived 2 to 12 days post injection (93/119), 73% (41/56) survived to term of which 68% (38/56)
survived and appeared normal one week after birth. At E7.5, the amniotic and exocoelomic cavities, and
ectoplacental cone region were discernable. Our success at targeting with few or no beads off-target was 90%
(36/40) for the ectoplacental cone region and 81% (35/43) for the exocoelomic cavity but tended to be less, 68%
(34/50), for the smaller amniotic cavity. At E11.5, beads microinjected at E7.5 into the ectoplacental cone region
were found in the placental spongiotrophoblast layer, those injected into the exocoelomic cavity were found on
the surface or within the placental labyrinth, and those injected into the amniotic cavity were found on the surface
or within the embryo. Following microinjection at E7.5, survival one week after birth was 60% (26/43) when the
amniotic cavity was the target and 66% (19/29) when the target was the ectoplacental cone region. The survival
rate was similar in sham experiments, 54% (33/61), for which procedures were identical but no microinjection
was performed, suggesting that surgery and manipulation of the uterus were the main causes of embryonic death.
Conclusion: Ultrasound-guided microinjection into the ectoplacental cone region at E6.5 or E7.5 and the
amniotic cavity at E7.5 was achieved with a 7 day postnatal survival of ≥60%. Target accuracy of these sites and
of the exocoelomic cavity at E7.5 was ≥51%. We suggest that this approach may be useful for exploring gene
function during early placental and embryonic development.
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Background
In utero microinjection of mouse embryos has proven val-
uable for exploring the developmental consequences of
altering gene expression using adenoviral or retroviral vec-
tors [1-12], or for injecting cells to study cell lineage or
migration [13,14]. Microinjection is also a useful
approach for rescuing mutant embryos to validate gene
therapies and/or circumvent embryonic morbidity or
mortality thereby permitting study of a gene's role later in
development or adulthood [15]. This approach has been
largely limited to studying embryos at embryonic day 9.5
(E9.5) or greater when the uterus and decidua have
become thinner and the placenta and embryo are rela-
tively large so that ultrasound or trans-illumination can
be used to guide injections into the conceptus in the exte-
riorized uterus. However, knocking out or mutating genes
critical for early development of the yolk sac, chorioallan-
toic placenta, hematopoietic system, embryonic heart and
vasculature often cause embryonic lethality before E9.5
[16-18]. Thus, the goal of the current study was to develop
Anatomical detail visible in ultrasound images Figure 1
Anatomical detail visible in ultrasound images. Ultrasound images (A, C) and H&E histological sections (B, D) of implan-
tation sites at E6.5 (A, B) and E7.5 (C, D). Divisions in the scale in A and C are 100 µm apart. The conceptus in histological sec-
tions is smaller than in vivo due to shrinkage during tissue preparation (fixation and dehydration). AC, amniotic cavity; Al, 
allantois; Emb, embryo; EPC, ectoplacental cone region; Exo, exocoelomic cavity.
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and validate methods to accurately target specific regions
of the conceptus under high-resolution ultrasound guid-
ance at E6.5 to E7.5 of gestation. At this stage, the embryo
is not yet dependent on placental or circulatory function
for survival. We show that ultrasound-guided microinjec-
tion into the ectoplacental cone region at E6.5 or E7.5 and
the amniotic cavity at E7.5 was achieved with a 7 day post-
natal survival of ≥60% and that target accuracy of these
sites and of the exocoelomic cavity at E7.5 was ≥51%, sug-
gesting this method will provide a feasible approach for
future studies.
Results and discussion
Ultrasound imaging of the early embryo
We used a 40 MHz ultrasound transducer to image the
conceptus within the exteriorized uterus in isoflurane-
anesthetized pregnant mice, and compared results with
histological images of the conceptus obtained at the same
gestational ages (figure 1). At E6.5, a relatively echogenic
(bright) ectoplacental cone region and a small echolucent
(dark) cavity containing the embryo was visualized inside
a ~1.5 mm thick decidua. The 3 dimensional (D) impres-
sion of the E6.5 conceptus in real-time (additional file 1)
was clearer than was evident from 2D still images (figure
1A). The most prominent structure in the conceptus at
this stage was the cone-shaped ectoplacental cone region
where embryonic trophoblast cells are invading the mes-
ometrial maternal decidua and where the future placenta
will develop. This region is bordered by echogenic cal-
cium deposits [19] making it an easily identified target on
ultrasound. The diameter of the proamniotic cavity con-
taining the embryo was ~150 µm at E6.5, which was near
the limit of resolution of the ultrasound transducer (50
µm [20]) and the outer diameter of the microinjection
pipette (50–80 µm). Thus, only the larger echogenic ecto-
placental cone region presented a feasible target at this
gestational age.
At E7.5, the amniotic and exocoelomic cavities, and the
ectoplacental cone region were each discernable on ultra-
sound (figure 1C). When compared to an appropriate his-
tological section at the same gestation (figure 1D), the
structural detail in the ultrasound image can be appreci-
ated. As at E6.5, the 3D impression of the E7.5 conceptus
observed in real-time (additional file 2) was clearer than
in 2D still images (figure 1C).
Dissection to establish conditions for accurate bead 
microinjection
The maximum injection volume that resulted in few or no
beads off-target was determined in 4 mice at E7.5 as fol-
lows. We began by microinjecting an aqueous suspension
of 3 µm diameter green fluorescent beads into the amni-
otic cavity at a volume of 207 nL, which was approxi-
Off-target beads following 69 nL microinjection into the amniotic cavity Figure 2
Off-target beads following 69 nL microinjection into the amniotic cavity. This E7.5 conceptus was dissected a few 
hours after ultrasound-guided microinjection of a 69 nL volume containing 3 µm diameter fluorescent beads into the amniotic 
cavity. (A) The amniotic and yolk sac cavities were visibly distended (e.g. compare to figure 3D) when viewed under a dissec-
tion microscope. (B) When the same embryo was viewed under a fluorescent microscope, beads were visible within the amni-
otic cavity (arrow) but were also present in the adjacent exocoelomic cavity as well as in the ectoplacental cone region. AC, 
amniotic cavity; EPC, ectoplacental cone region; Exo, exocoelomic cavity; YSC, yolk sac cavity.
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mately 50% of the lowest previously published volume
[1]. This caused marked distension of the cavity and sur-
rounding area so we gradually reduced the volume to 13.8
nL in successive experiments. Injection accuracy and fre-
quency of beads in adjacent off-target areas was visually
evaluated using a stereomicroscope in implantation sites
that were dissected as previously described [21] within a
few hours following microinjection.
We found that microinjection volumes of 69 nL or more
into the E7.5 amniotic cavity visibly distended the cavity.
At necropsy, the injected 3 µm diameter fluorescent beads
were frequently found in adjacent off-target cavities (fig-
ure 2A, B). This is consistent with our volume estimate of
~50 nL for the embryo and both cavities (based on an
ellipsoid of approximately 0.3 mm diameter × 1 mm
length). Distension and beads in adjacent off-target
regions were minimal when a volume of 13.8 nL was
injected at a rate of 23 nL/s.
With a suitable injection volume of 13.8 nL established,
we next evaluated the accuracy of targeting the amniotic
cavity (additional file 3), exocoelomic cavity (additional
file 4), and the ectoplacental cone region (additional file
5) at E7.5 (table 1). The accuracy of targeting the ectopla-
cental cone region at E6.5 was similarly determined (table
1). A few hours following microinjection, mice were euth-
anized then dissected under a stereomicroscope and the
Table 1: Target accuracy following micro-injection.
Age Target Necropsy Mice Concepti1 Beads in conceptus2 Beads localized in target3
###%#% 9 5 %  C I
E6.5 EPC Within 24 
hours
5 5 55 09 12 8 5 1 * 3 8 – 6 4
E7.5 EPC Day of 
injection
4 4 03 89 53 69 0 7 7 – 9 6
E7.5 AC Day of 
injection
4 5 04 79 43 46 8 5 4 – 7 9
E7.5 Exo Day of 
injection
4 4 34 09 53 58 1 6 8 – 9 1
1 number of concepti analyzed (<10% were damaged during dissection and were not included)
2 number of concepti containing beads at one or more sites
3 number of concepti with beads localized in target with few or no beads off-target
* significantly different than EPC at E7.5
EPC = ectoplacental cone region, AC = amniotic cavity, Exo = exocoelomic cavity, CI = confidence interval
Target accuracy Figure 3
Target accuracy. Concepti dissected a few hours after ultrasound-guided microinjections of a 13.8 nL volume containing 3 
µm diameter fluorescent beads. In these examples, there were few (e.g. arrows in A&D) or no beads considered off-target (e.g. 
B&C). The ectoplacental cone region was targeted in (A) at E6.5 and (B) at E7.5. At E7.5, the exocoelomic cavity (C) and amni-
otic cavity (D) were also targeted. AC, amniotic cavity; EPC, ectoplacental cone region; Exo, exocoelomic cavity.
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concepti placed in a 96-well plate filled with calcium and
magnesium-free phosphate-buffered saline (PBS). Each
conceptus was examined under a stereomicroscope and
the location of fluorescent beads recorded (figure 3). Less
than 10% of injected concepti were damaged during dis-
section and were excluded from analysis. Greater than
90% of concepti contained beads (table 1) but they were
not always confined to the target. Microinjections where
many beads were off-target were excluded from the "on
target" count because they were considered inaccurate
even if some beads were in the targeted location. Exam-
ples of "on target" microinjections are shown in figure 3.
At E6.5, a volume of 13.8 nL microinjected at a rate of 23
nL/s into the ectoplacental cone region resulted in beads
being present in 91% of concepti (50/55) (table 1). How-
ever, beads were specifically localized to the ectoplacental
cone region in only 51% of those injected (28/55). Use of
a smaller injection volume may improve accuracy at this
age. Targeting accuracy of the ectoplacental cone region
was significantly improved at E7.5 (i.e. no overlap in 95%
confidence intervals relative to survival at E6.5). At E7.5,
beads were localized to the ectoplacental target in 90% of
concepti (36/40) (table 1) (figure 3A, B). In 50 µm frozen
tissue sections at E7.5, fluorescent beads were visible in
the ectoplacental cone region (figure 4) suggesting that
beads could be used in future studies to mark the site of
microinjection in histological sections [22]. At E7.5, we
were also able to target the exocoelomic and amniotic cav-
ities. Our success at targeting with few or no beads off-tar-
get was 81% for the exocoelomic cavity and 68% for the
smaller amniotic cavity (table 1, figure 3C, D).
Assessment of embryonic survival and effect of 
development on localization of beads
Embryonic survival following microinjection was deter-
mined up to 1 week following birth (table 2). Between
E7.5–18.5, mice injected at E6.5 were euthanized, the
uterus removed, and the individual embryos dissected.
Embryos with normal coloration, and without evidence of
autolysis were considered to have survived. Additional
mice were allowed to progress to delivery. The number of
live pups on the day of birth (either at cesarean section or
following spontaneous delivery), and at one-week post
delivery was determined. The number of survivors relative
to the number of injected sites was determined for each
mouse. The localization of beads was determined up to 7
days post microinjection. Determination at later time
points was more difficult because of rarefaction of the
beads due to growth and development of the tissue mass
containing the beads, and the inability to detect beads
embedded within the embryo or placenta due to
increased tissue opacity.
Ectoplacental cone region
Following microinjection into the ectoplacental cone
region at E6.5, 78% of embryos in 10 mice were still alive
when assessed 2 to 12 days later, 73% of pups from 4 mice
were still alive at birth, and 68% were still alive at 1 week
of age (table 2). In 7 of the 10 mice evaluated during preg-
nancy, the conceptus was dissected within 7 days post
injection and the localization of beads was assessed by
gross morphology. 74% (62/84) of the embryos were
alive of which 95% (59/62) had beads in the conceptus.
95% (56/59) of these had beads predominantly localized
to the placental region.
Following microinjection into the ectoplacental cone
region at E7.5, 89% of embryos in 8 mice were still alive
when assessed 2–12 days later (table 2). In 6 of these
mice, the localization of beads was determined by gross
morphology. 79% (55/70) of the embryos survived of
which 96% (53/55) had beads in the conceptus. 94% of
these (50/53) had beads predominantly localized to the
placental region. Histology was performed on 7 concepti
with surviving embryos from one pregnant mouse at
E11.5 to determine the location of beads more precisely
using 50 µm frozen sections. The vast majority of injected
beads were localized in the placental spongiotrophoblast
Histological detection of injected beads Figure 4
Histological detection of injected beads. Implantation 
site (tissue autofluoresces orange) containing green fluores-
cent beads collected a few hours following ultrasound-guided 
microinjection into the ectoplacental cone region at E7.5. 
Beads visualized in 50 µm frozen sections were primarily 
localized to the targeted ectoplacental cone region. AC, 
amniotic cavity; Emb, embryo; EPC, ectoplacental cone; Exo, 
exocoelomic cavity; YSC, yolk sac cavity.
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layer (figure 5B–D). A few beads were often observed
between the yolk sac membranes, and a few beads were
occasionally observed in the labyrinth or amniotic cavity.
Localization of beads within the spongiotrophoblast layer
is consistent with the ectoplacental origin of cells in this
layer [24]. 66% of pups of 2 mice were still alive at 1 week
after birth. Surviving neonates had no apparent abnor-
malities in morphology or body size.
Exocoelomic cavity
When we performed microinjection into the exocoelomic
cavity at E7.5, 78% of embryos in 6 mice were still alive
when assessed 2–12 days later (table 2). The localization
of beads in 4 of these 6 mice was assessed in concepti with
surviving embryos by gross morphology. 90% (45/50)
had beads in the conceptus and in all cases the majority of
beads were present in the placental region. While assess-
ing the location of the beads we noted that the fluorescent
beads were visible, trapped on the placental surface (fig-
ure 6A). In 2 of these mice we further assessed the location
of the beads within the placenta by performing 50 µm fro-
zen sections at E11.5 and found the fluorescent beads to
be distributed deep within the placental labyrinth in
cross-sections (figure 6B–D). This was observed in 80%
(21/26) of placentas from surviving embryos in the 2 mice
that were assessed. Possibly beads within the exocoelomic
cavity and/or beads adherent to the allantois or chorionic
surfaces following injection into this cavity became
trapped following allantoic attachment and subsequent
invasion into the chorion, and by this means were carried
deep into the developing labyrinth during chorio-allan-
toic morphogenesis [23,24].
Amniotic cavity
We assessed survival after microinjection of the amniotic
cavity at E7.5 in 15 mice. 68% of embryos were still alive
when assessed 2–12 days post injection. The distribution
of beads was assessed in 33 embryos from 3 pregnant
mice 2 days following microinjection into the amniotic
cavity at E7.5. 82% (27/33) survived and all had beads
within the conceptus. 62% (17/27) of the surviving
embryos were found to have fluorescent beads on their
skin and deep within their structure. The deeper beads
may have become trapped within the neural tract during
neural tube closure (figure 7). 73% (38/52) of similarly
injected surviving embryos examined 4–8 days following
microinjection at E7.5 had beads visible within their skin
surface. At this stage, tissue opacity made detection of
deeper beads difficult to assess. 60% of pups of 3 mice
were still alive at birth and at 1 week of age (table 2). Sur-
viving neonates had no apparent abnormalities in mor-
phology or body size.
Sham experiments
We performed sham experiments to assess the effect of
microinjection on embryo viability. We also determined
survival in non-operated control pregnancies. For sham 1,
all experimental procedures at E7.5 were replicated except
no microinjection was performed (surgical exposure,
ultrasound imaging, uterine manipulation, and experi-
mental duration were replicated). For sham 2, uterine
Table 2: Survival following microinjection or sham procedures.
age at intervention E6.5 E7.5 E7.5 E7.5 E7.5 E7.5
target EPC EPC Exo AC Sham 1 Sham 2
Embryo 2–12 d postinjection
#  m i c e 1 08 61 56n d
# concepti 119 76 64 145 90 nd
# alive 93 68 50 98 60 nd
%  a l i v e 7 8 8 9  † 7 86 86 7n d
95% CI for % alive 70–85 80–95 66–87 59–75 56–76 nd
At birth
#  m i c e 4 n d n d 355
# concepti 56 nd nd 43 61 62
# alive 41 nd nd 26 34 52
% alive 73 nd nd 60 56 * 84
95% CI for % alive 60–84 nd nd 40–75 42–68 72–92
1 wk Postnatal
#  m i c e 42 n d 355
# concepti 56 29 nd 43 61 62
# alive 38 19 nd 26 33 52
% alive 68 66 nd 60 54 * 84
95% CI for % alive 54–80 46–82 nd 44–75 41–67 72–92
nd = not done; # = number; CI = confidence interval; EPC = ectoplacental cone region; Exo = exocoelemic cavity; AC = amniotic cavity; Sham 1 = 
surgical procedure and ultrasound imaging without microinjection; Sham 2 = brief surgery to count embryos; † = % alive significantly greater than 
for AC and Sham 1; * = % alive in Sham 1 is significantly less than in Sham 2BMC Developmental Biology 2006, 6:10 http://www.biomedcentral.com/1471-213X/6/10
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horns were exposed at E7.5 to count the number of
implantation sites and then were immediately replaced.
For normal survival in non-operated control pregnancies,
we determined embryonic number as a function of gesta-
tional age in control mice without prior interventions. We
examined an average of 15 pregnant mice per gestation
day from E6.5 to E18.5 at necropsy, and counted the
number of viable embryos. Linear regression was used to
show that the average number of embryos at E0 was 14
and the rate of embryo loss per day was 0.13. This infor-
mation was used to calculate the average embryonic sur-
vival rate in pregnancies without interventions at specific
gestational ages.
In sham 1, 54% of embryos were alive and appeared nor-
mal when assessed at 1 week postnatal age (table 2). This
rate did not differ significantly from survival rates follow-
ing microinjection into the amniotic cavity (60%) or the
ectoplacental cone region (66–68%) (i.e. there was over-
lap in 95% confidence intervals) indicating that the
embryonic lethality was predominantly due to the surgi-
cal procedure not to the microinjection procedure. In
sham 2, survival at 1 week postnatal age was 84% which
Localization of fluorescent beads in the spongiotrophoblast layer following ectoplacental cone microinjection Figure 5
Localization of fluorescent beads in the spongiotrophoblast layer following ectoplacental cone microinjection. 
(A) Placement of the micropipette tip (arrow) near the center of the ectoplacental cone region (EPC) at E7.5. The EPC is 
demarcated by an echogenic 'V'-shape (arrowhead) [19], and is therefore easy to identify on ultrasound. (B-D) Histological 
images obtained from a conceptus at E11.5 following microinjection of green fluorescent beads into the EPC at E7.5. Frozen 
sections were counterstained with DAPI (nuclei stain blue) and immunofluorescence was used to detect collagen 4 in the base-
ment membrane of the labyrinth capillaries (pink). The beads are localized in the placental spongiotrophoblast layer between 
the labyrinth and the decidua. Boxed regions in (B) and (C) are shown as higher power images in (C) and (D) respectively. AC, 
amniotic cavity; Emb, embryo; Sp, spongiotrophoblast layer; US, uterine stabilizer.
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was significantly higher than in Sham 1 (54%) (table 2).
Sham 2 survival at birth (84%) was close to the 89% sur-
vival expected for non-operated control pregnancies.
Thus, optimal embryonic survival depends upon keeping
the duration of the surgical procedure short and minimiz-
ing uterine manipulation.
Conclusion
Ultrasound-guided microinjection provides a feasible
approach for experimental interventions into either the
embryonic (E7.5) or extra-embryonic (E6.5–7.5) regions.
Limitations include the presence of beads in off-target
locations and a significant increase in embryonic deaths.
In the current study we injected fluorescently labeled
microspheres in vehicle (0.9% saline). In future studies
the vehicle could include inhibitory RNA, transfection
vectors, specific antibodies, or labeled cells and thus this
method could be used to explore the developmental con-
sequences of altering gene expression, or for studying cell
lineage and migration. However, whether the localization
of cells, small molecules or solutes would be similar to
that of the beads used in the current study is unknown.
Localization of fluorescent beads in the placental labyrinth following exocoelomic microinjection Figure 6
Localization of fluorescent beads in the placental labyrinth following exocoelomic microinjection. Images of pla-
centas dissected at E11.5 following ultrasound-guided microinjection of green fluorescent beads into the exocoelomic cavity at 
E7.5. (A) Stereomicroscopic image showing fluorescent beads embedded in the fetal surface of the placenta near the cord 
insertion. (B) 50 µm frozen section through the placenta and implantation site showing fluorescent beads distributed within the 
labyrinth layer, extending as deep as the border between the labyrinth and spongiotrophoblast layers (dotted line). Boxed 
regions in (B) and (C) are shown as higher power images in (C) and (D) respectively. Cell nuclei were stained with DAPI in B, 
C, and D. AC, amniotic cavity; Emb, embryo.
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This limitation may be addressed by microinjecting bioac-
tive agents tagged or absorbed to spheres, or by microin-
jecting cells that are labeled so that spheres or cells can be
localized later either grossly during dissection or in histo-
logical sections.
We speculate that microinjections into the exocoelomic
cavity may be useful for studies of the development of the
yolk sac (e.g. vascularization and hematopoiesis), the
interactions between the allantois and chorioallantoic
placenta (e.g. chorio-allantoic fusion and morphogene-
sis) and the development of the placental labyrinth layer.
In addition, the ectoplacental cone region can be targeted
directly, thereby placing agents among relatively undiffer-
entiated, early placental trophoblasts. Since umbilical
blood flow does not commence until approximately E9.5
[20,25], injected agents are likely to remain within this
target location and not circulate systemically in the
embryo unlike placental injections performed in later ges-
tation. Microinjections into the amniotic cavity may be
useful for influencing early events in embryonic develop-
ment such as gastrulation, axis formation, and neural tube
closure.
Methods
The study protocol was approved by the Mount Sinai Hos-
pital Animal Care Committee, and was conducted in
accord with the guidelines of the Canadian Council on
Animal Care.
Animals and animal-related procedures
CD-1 mice (Charles River [28]) were naturally mated. Day
0.5 of gestation was defined as noon on the day a vaginal
plug was found after overnight mating. All procedures
were carried out in a laminar flow hood. Anesthesia was
induced in a chamber then maintained by facemask with
1.5% isoflurane. Body temperature was monitored via rec-
tal thermometer and maintained at 35–38°C using a heat-
ing pad and lamp, and heart rate was monitored by
electrodes attached to the paws (Indus Instruments [29]).
Maternal well-being was carefully monitored to maintain
an appropriate body temperature, heart rate, respiratory
vigor, and anesthetic depth throughout the procedure. All
hair was removed from the abdomen by shaving followed
by a chemical hair remover (Nair, Carter-Horner Inc.
[30]). The skin was cleansed with 70% ethanol, and the
abdomen opened with a 2 cm vertical midline incision
along the linea alba (midline avascular region). The stage
upon which the mouse was mounted (figure 8) was tilted
head down (between 35–45°) to displace the bowel, the
uterine horns were gently exteriorized, and the number of
implantation sites recorded. The uterine horns were
replaced in the abdominal cavity except for a short seg-
ment containing 1–3 implantation sites at the ovarian end
of the right horn. This segment was positioned just below
the skin at the incision site. The maternal skin was re-dried
using a small amount of alcohol and a cotton swab.
A modified Petri dish (100 mm diameter, 25 mm deep),
similar to that used in earlier work on older embryos
[1,2,13,14,26,27], was positioned above the incision site
as follows (figure 8C). The Petri dish had a 25 mm hole in
the bottom, which was sealed from below by a thin trans-
parent rubber membrane (40 mm square [31]). The mem-
brane had a 10 × 1 mm slit cut in the centre, which was
positioned above the skin incision (figure 8C). Fine for-
ceps were passed through the slit in the rubber mem-
brane, the skin edges were gently apposed, and pulled up
while the dish and membrane were placed against the
maternal skin. Pulling up on the skin in this manner
helped create a watertight seal as well as keeping the skin
accessible so it could later be held in place while retrieving
and replacing the uterus. Using fine forceps, the slit edge
and its apposing skin edge were lifted to reveal the under-
Embryonic localization of fluorescent beads following amni- otic cavity microinjection Figure 7
Embryonic localization of fluorescent beads following 
amniotic cavity microinjection. E9.5 embryo dissected 2 
days after ultrasound-guided microinjection of 13.8 nL of flu-
orescent beads into the amniotic cavity. Green fluorescent 
beads were visible within the neural system (arrows) as well 
as on the skin surface. The embryo was imaged using a Leica 
MZ 16FA stereomicroscope with GFP filter.
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lying uterine segment. Using a second pair of forceps, the
uterine segment was gently exteriorized by grasping
between implantations sites. At this stage, the transparent
membrane was checked to ensure it was still adherent to
the maternal skin suggesting an intact watertight seal.
The Petri dish was then supported by Plasticene blocks
and filled with calcium and magnesium-free phosphate-
buffered saline (PBS) (figure 8C). The PBS served as an
ultrasound-coupling medium, maintained hydration of
the uterus, and was used at room temperature to reduce
normal resting myometrial activity (and therefore the
associated gross movements of the implantation sites).
The exposed uterine segment was short, ~1–3 implanta-
tion sites, which helped stabilize the segment during uter-
ine activity and during microinjections. It was supported
laterally by a semi-circular sheet of Silicone rubber (Silas-
tic L RTV silicone rubber; Dow Corning [32]), which was
submerged next to it inside the Petri dish on the side
opposite that of the microinjector (figure 8C). This 'uter-
ine stabilizer' was cast in a modified Petri dish and then
bisected prior to use.
After microinjecting all sites as described in detail below,
the maternal abdomen was closed using 6-0 silk, (Sof-
silk™, United States Surgical Corporation [33]) using a
continuous suture for the peritoneum and abdominal
muscles and interrupted mattress sutures (3–4) for the
skin. Anaesthesia was discontinued and the mouse was
placed in a heated recovery chamber. Usually the mouse
Microinjector apparatus and experiment set-up Figure 8
Microinjector apparatus and experiment set-up. (A) The rail system maintains the alignment of the image plane of the 
ultrasound transducer (1) with the trajectory of the microinjector (2). The stage (3) on which the mouse is placed is adjusted 
to place the target region of the conceptus in the image plane by adjusting the position of the stage using the XYZ controls (4). 
The rail system increases efficiency by reducing time to target acquisition, improving accuracy and as a result contributes to 
improved overall survival. (B) The sharp bevelled tip of the microinjection pipette is shown. (C) A modified Petri dish contain-
ing PBS (5) is supported above the mouse using Plasticene blocks (6). A segment of the uterus is exposed through a small mid-
line abdominal incision into the Petri dish. A thin transparent rubber membrane (7) attached to the under surface of the Petri 
dish (5) seals the dish to the dry denuded maternal skin (8), while a thicker silastic membrane (9) submerged within the Petri 
dish stabilizes the uterus during microinjection.
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was awake and active within 5–10 minutes. No pregnant
mice died or aborted following microinjection at E6.5 or
E7.5 in over 100 procedures performed to date.
High frequency ultrasound
We used an ultrasound biomicroscope (UBM) with a 40
MHz probe (Vevo-660™; VisualSonics) for real-time (34
frames/s) microvisualization of the conceptus and micro-
injection pipette. The 40 MHz probe has a spatial resolu-
tion of ~50 µm at 40 MHz [20]. The mouse was mounted
on the stage of a rail system (VisualSonics), which permit-
ted the operator to readily adjust the position of the
mouse while maintaining the microinjection pipette
within the transducer-imaging plane (figure 8A).
Micropipette preparation
Microinjection pipettes were prepared using methods
adapted from prior work [27]. Glass microcapillary tubes
(3 1/2 "replacement tubes" Drummond Scientific Com-
pany, cat. # 3-000-203-G/X [34]) were pulled using a ver-
tical puller (Narishige PB-7 [35]) to produce a long taper.
Pipettes were broken using forceps or a scalpel blade in
Practical points to improve accuracy Figure 9
Practical points to improve accuracy. (A) Diagram of the optimum experimental set-up enlarged from that shown in fig-
ure 8. The uterine stabilizer (1) is cast in one of the modified Petri dishes so that it extends into the central hole (2). As a result 
the uterine stabilizer fits more closely to the transparent membrane (3) attached to the under surface of the petri dish and also 
creates a more secure seal with the skin of the mouse abdomen (4). This is important because it reduces the possibility of the 
exposed segment of uterine horn slipping between the under surface of the stabilizer and the transparent rubber membrane or 
the maternal skin during microinjections. Keeping the exposed uterus closely approximated to the uterine stabilizer (dotted 
oval labelled 5 in A &C) is very important in improving accuracy of microinjections. This improves stability of the uterine seg-
ment during microinjection allowing easier penetration of the micropipette through the thick uterine muscle enabling a more 
accurate placement of the tip of the microinjection pipette into the target region. (B) If the uterus is separated from the edge 
of the uterine stabilizer (double-headed arrow), the uterus will move away from the advancing needle and the target area of 
the conceptus will move out of the focal zone and/or field of view of the transducer reducing the accuracy of the microinjec-
tions. (C) The optimal position of the uterus relative to the uterine stabilizer is demonstrated. The alignment of the conceptus 
within the scan plane is also optimal. In this position three potential targets are easily accessible from a lateral approach 
thereby avoiding injury to the embryo caused by the microinjection pipette or the inadvertent deposition of fluorescent beads 
in other targets during needle insertion or withdrawal. (D) Placement of the microinjection pipette within the amniotic cavity 
(arrow). (E) Immediately after removal of the microinjection pipette, a small amount of echogenic material (fluorescent beads) 
can be seen within the amniotic cavity (arrow) which was not present prior to microinjection (compare with amniotic cavity in 
image B).
C D E
5
micropipette
3
A
5
4
40mHz probe
PBS
micropipette
B
1
2
1BMC Developmental Biology 2006, 6:10 http://www.biomedcentral.com/1471-213X/6/10
Page 12 of 14
(page number not for citation purposes)
the narrowed region under a dissection microscope and
the tip diameters were measured using the calibrated
length scale in the eyepiece of the microforge (Narishige
MF-9). Pipette tips with an outer diameter of approxi-
mately 50–80 µm and inner diameter of approximately
40–50 µm were gradually beveled to 20 degrees (figure
8B) using a continuously moistened grinder for 20 min-
utes (Narishige EG-4). Too little moisture resulted in a
high incidence of tips blocked by particles following the
grinding process. All tips were carefully inspected after
sharpening to ensure the tip was clear and sharp (figure
8B).
The microinjection pipette was filled with mineral oil
before connecting it to the microinjector using the manu-
facturer's instructions (Nanoject II; Drummond Scientific
Co.). Once attached, excess oil was expelled. Green fluo-
rescent beads (polystyrene latex, 3.0 ± 0.1 µm diameter,
2.5% solids in water; 1.68 × 103 particles/nl; Fluoresbrite™
YG Microspheres; Polysciences [36]) were diluted 2:1 in
saline. With the aid of a stereomicroscope (Leica, MS5
[37]) and micromanipulator, the tip of the microinjection
pipette was positioned in a 15 µL drop of the bead mix-
ture and the mixture aspirated using the microinjector
controls immediately prior to use. The filling procedure
was visually monitored using the stereomicroscope to
ensure no air was aspirated and that the pipette tip did not
touch the bottom of the dish to prevent the tip from being
blunted or broken. When the microinjection pipette was
filled, the microinjector was transferred to the microman-
ipulator on the rail system, for alignment within the ultra-
sound scan plane.
Microinjection procedure
The microinjection pipette was imaged in PBS prior to the
experiment. It was aligned in the scan plane using the XYZ
controls so that the tip was centred within the focal zone
of the transducer (area of image with the greatest resolu-
tion). This position, 'the guide point', was recorded by the
UBM and remained displayed on the monitor. The pipette
was then retracted leaving the tip in PBS to prevent dehy-
dration-induced obstruction of the lumen.
During experiments, implantation sites were moved into
the scan plane using the XYZ controls on the mouse stage.
The target region of the conceptus was positioned at the
guide point displayed on the UBM's monitor, and then
the microinjection pipette was advanced until the tip was
visible within the target region. The injectate was then
administered at a rate of 23 nL/s (Nanoject II; Drummond
Scientific Company). Injected beads were echogenic when
injected into cavities thereby permitting a visual impres-
sion of targeting success (figure 9E). Accuracy was
improved by ensuring the uterine segment was directly
adjacent to the 'uterine stabilizer' at the time of microin-
jection (figure 9A, C) and by the sharpness of the micro-
injection pipette, both of which minimized the
movement of the uterus as the microinjection pipette
advanced. Using a lateral approach to microinject the
three-targeted regions also helped to improve accuracy.
This approach avoids passage of the needle through non-
targeted regions of the conceptus and the associated risk
of mechanical injury or deposition of beads in these
regions. The time of microinjection was coordinated with
the spontaneous motion of the uterine segment (caused
by uterine muscle activity) to optimise alignment of the
uterine segment against the 'uterine stabilizer' and the
path of the microinjection pipette to the target (figure 9B–
D).
After injecting the 1–3 exposed sites, they were replaced
and the uterine segment containing the next 1–3 implan-
tation sites was carefully removed from the abdominal
cavity, pulled gently through the water seal membrane
into the PBS-filled Petri dish and was laid next to the uter-
ine stabilizer. The patency of the microinjection pipette
was confirmed before continuing.
We microinjected the targeted region within each site in
both uterine horns (usually 10 to 16 sites) within 20 to 30
minutes (demonstration in additional files 3, 4, 5) using
two operators. One operator loaded and discharged the
needle and took notes, while the other performed surgery,
operated the UBM, and positioned the microinjection
pipette in the target area. Abnormal sites that appeared to
contain embryos undergoing re-absorption had their
positions noted but were not injected.
At necropsy, the localization of beads was visually evalu-
ated using a stereomicroscope (Leica, MS5 [37]) with an
attached universal light source (MAA-002 from BLS Ltd.
[38]) in implantation sites that were dissected as previ-
ously described [21].
Histology
Histology was performed on implantation sites that were
immersion-fixed in 4% paraformaldehyde, dehydrated in
alcohol, and paraffin embedded. Tissue was sectioned (5
µm) and stained with hematoxylin and eosin (H&E) to
show general morphology of the implantation site for
comparison with ultrasound images (figure 1B, D). In
order to detect the fluorescent beads, 50 µm frozen sec-
tions of paraformaldehyde-fixed sites were imaged using
an inverted microscope with a FITC filter to detect the flu-
orescent beads. Images showing the beads were superim-
posed on autofluorescent images of the tissue obtained
using a CY-3 filter (tissue autofluoresces red/orange, fig-
ure 4) or using immunofluorescence to detect collagen 4
(basement membranes of blood vessels appear pink, fig-
ure 5B–D) and/or following counterstaining with 4', 6-BMC Developmental Biology 2006, 6:10 http://www.biomedcentral.com/1471-213X/6/10
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Diamidino-2-phenylindole (DAPI; DNA fluoresces blue,
figure 6B–D).
Statistics
95% confidence intervals were used to determine statisti-
cal significance when comparing target accuracy between
the different target sites at E6.5 and E7.5 and when com-
paring survival between the experimental and sham
groups. Linear regression was used to calculate the average
number of embryos at a given gestation in non-operated
control pregnancies. P < 0.05 was considered significant.
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